Fused Bicyclic FXR Modulators for Lipid Homeostasis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for hyperlipidemia and related metabolic disorders, such as nonalcoholic steatohepatitis (NASH), are inadequate in effectively lowering triglycerides and non-HDL cholesterol, particularly in patients with cardiovascular disease, diabetes, and metabolic syndrome.

Innovation Solution

Development of compounds, such as those represented by Formulas (I) to (Xa), which act as FXR modulators to regulate bile acid and lipid homeostasis, thereby reducing triglyceride levels and improving lipid profiles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If current treatments for hyperlipidemia are used, then patient compliance is maintained, but triglyceride and non-HDL cholesterol levels are not effectively lowered

Engineering Contradiction:
Improvetriglyceride levelsVSAvoidtreatment effectiveness
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent employs parameter changes by developing novel chemical compounds with modified molecular structures (Formulas I-Xa) that exhibit enhanced FXR modulating activity. These structural modifications include variations in R1-R8 substituents and bicyclic core structures, which change the pharmacological parameters to achieve superior triglyceride and cholesterol lowering effects compared to existing treatments

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If FXR modulating compounds are administered, then lipid homeostasis is improved and triglycerides are lowered, but the complexity of treatment regimens increases

Engineering Contradiction:
Improvelipid homeostasisVSAvoidtreatment regimen complexity
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent applies universality by designing FXR modulating compounds that simultaneously address multiple lipid abnormalities - lowering triglycerides, reducing non-HDL cholesterol, and improving overall lipid homeostasis. This multi-functional approach allows a single compound to treat several aspects of dyslipidemia, simplifying the treatment regimen despite the molecular complexity of the compounds themselves

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250171446A1Fused bicyclic compounds for the treatment of disease
Publication Date: 2025.05.29 ABBVIE INC
  • US20250171446A1 patent drawing
  • US20250171446A1 patent drawing
  • US20250171446A1 patent drawing

AI summary

Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.